Regarding the Sept. 13 front-page article “Stem-cell clinics face new scrutiny from FDA”:
The Food and Drug Administration should monitor stem-cell clinics and ask for permission to collect data to better make decisions regarding regulation. There is not enough substantial data to draw conclusions.
The FDA should be concerned about these clinics and treatments because the process is a promising and developing field riddled with hearsay. The FDA (ideally) has the interests of the public in mind when raising concerns and would not regulate clinics and cause losses in profits without concern over dangerous or simply unhelpful treatments that consumers fall for. The placebo effect and other treatments may play major roles in people’s recoveries, as the article mentioned. For example, one could not know if the stem-cell treatment or something else aided in the recovery of the person mentioned who suffered a sports-related injury in the shoulders. Even if these therapies are shown to correlate with recovery, that does not imply causation.
A comprehensive large-scale study is necessary to scientifically confirm the validity of these treatments.
Telon Yan, Gaithersburg